{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:30:16Z","timestamp":1770503416344,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.euroneuro.2009.03.003","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T09:14:40Z","timestamp":1244193280000},"page":"542-550","source":"Crossref","is-referenced-by-count":33,"title":["Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study"],"prefix":"10.1016","volume":"19","author":[{"given":"Diego","family":"Novick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Maria","family":"Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Marques","family":"Texeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2009.03.003_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/713847170","article-title":"Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study","volume":"29","author":"Bobes","year":"2003","journal-title":"J. Sex. Marital. Ther."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4088\/JCP.v68n0416","article-title":"Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia","volume":"68","author":"Brecher","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib7","series-title":"ECDEU Assessment Manual for Psychopharmacology","article-title":"Clinical Global Impression","author":"Guy","year":"1976"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2009.03.003_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinol."},{"issue":"Suppl 416","key":"10.1016\/j.euroneuro.2009.03.003_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-0447.107.s416.4.x","article-title":"The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1034\/j.1600-0447.2003.00064.x","article-title":"The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"issue":"Suppl 416","key":"10.1016\/j.euroneuro.2009.03.003_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1600-0447.2004.00450.x","article-title":"Effectiveness of antipsychotic treatment for schizophrenia: 6-months results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study","volume":"111","author":"Haro","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","article-title":"Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results","volume":"17","author":"Haro","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1185\/030079903125002865","article-title":"Hyperprolactinaemia and antipsychotic therapy in schizophrenia","volume":"20","author":"Hummer","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1600-0447.2004.00451.x","article-title":"Olanzapine versus other antipsychotics in actual outpatient settings: six months tolerability results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study","volume":"111","author":"Lambert","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YCO.0b013e328017f6c4","article-title":"Sexual dysfunction in schizophrenia","volume":"20","author":"Malik","year":"2007","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/appi.ajp.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 23","key":"10.1016\/j.euroneuro.2009.03.003_bib19","first-page":"23","article-title":"Mechanisms of antipsychotic-induced weight gain","volume":"62","author":"McIntyre","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia","volume":"50","author":"Margolese","year":"2005","journal-title":"Can. J. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2009.03.003_bib21","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.schres.2008.11.007","article-title":"Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study","volume":"108","author":"Novick","year":"2009","journal-title":"Schizo. Res."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0447.2006.00906.x","article-title":"Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK","volume":"115","author":"Pendlebury","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2009.03.003_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0924-9338(97)89490-4","article-title":"Sexual dysfunction: the unspoken side-effect of antipsychotics","volume":"13","author":"Peuskens","year":"1998","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevalence and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eurpsy.2007.07.002","article-title":"A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2\u00a0years","volume":"22","author":"Smith","year":"2007","journal-title":"Eur. Psychiatry"},{"issue":"3 Suppl 1","key":"10.1016\/j.euroneuro.2009.03.003_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.jcp.0000084037.22282.a3","article-title":"The implications of weight changes with antipsychotic treatment","volume":"23","author":"Sussman","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain: a systematic review","volume":"101","author":"Taylor","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib30","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4088\/JCP.v66n0907","article-title":"Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study","volume":"66","author":"Tenback","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.03.003_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics","volume":"159","author":"Turrone","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.eurpsy.2007.01.001","article-title":"Sexual dysfunction in patients with schizophrenia on antipsychotic medication","volume":"22","author":"U\u00e7ok","year":"2007","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.03.003_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","article-title":"EPS profiles: the atypical antipsychotics are not all the same","volume":"13","author":"Weiden","year":"2007","journal-title":"J. Psychiatr. Pract."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T13:44:46Z","timestamp":1685022286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X09000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0924977X09000893"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.03.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}